Axcelead DDP participates in “MONSTAR-SCREEN-2” of the industry-academia collaborative Cancer Genome Screening Project “SCRUM-Japan”
Axcelead Drug Discovery Partners (Axcelead DDP), the group company of Axcelead, Inc. announced that Axcelead DDP will participate as a joint research institution to support “MONSTAR-SCREEN-2” of the 4th-stage industry-academia collaborative Cancer Genome Screening Project for Individualized Medicine in Japan “SCRUM-Japan” led by the National Cancer Center Hospital East (Location: Kashiwa, Chiba, JAPAN, Director: Atsushi Ohtsu, hereinafter “NCCHE)”.
Axcelead DDP will play a part in elucidating cancer cells and the tumor immune microenvironment that surrounds them. We are confident that the solution provided by Axcelead DDP will greatly contribute to the acceleration of novel therapeutic drug development through this project. For details, please refer Axcelead DDP’s web-site (https://www.axcelead.com/en/news-release/5390/)